Using advanced imaging to assess kidney tumors and predict kidney function after surgery
Advanced Diffusion Imaging in Renal Cancer Patients: Oncologic Control and Renal Functional Reserve
NA · NYU Langone Health · NCT06116253
This study is testing if advanced imaging can help doctors understand kidney tumors better and predict how kidney function will change after surgery for people with certain kidney health levels.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 21 Years to 85 Years |
| Sex | All |
| Sponsor | NYU Langone Health (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06116253 on ClinicalTrials.gov |
What this trial studies
This study aims to utilize advanced diffusion imaging techniques to evaluate renal mass patients in two key areas: determining the malignancy and subtype of the lesions, and predicting the stability or decline of renal function following partial nephrectomy. Patients scheduled for laparoscopic partial nephrectomy will undergo MRI scans and Tc-99m Pentetate imaging as part of the assessment. The study focuses on patients with an estimated glomerular filtration rate (eGFR) above 30 ml/min/m2, aged between 21 and 85, who can provide informed consent.
Who should consider this trial
Good fit: Ideal candidates are renal mass patients aged 21 to 85 with an eGFR above 30 ml/min/m2 who are scheduled for laparoscopic partial nephrectomy.
Not a fit: Patients with metal implants that are unsafe for MRI, pregnant women, and those with acute claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of renal cancer assessments and improve patient outcomes following kidney surgery.
How similar studies have performed: While advanced imaging techniques have been explored in other contexts, this specific application in renal cancer assessment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Renal mass patients scheduled for laparoscopic partial nephrectomy. * eGFR above 30 ml/min/m2. * Ages 21 to 85 * Must be willing and able to provide consent. Exclusion Criteria: * All metal implants and dental implants that have ferromagnetic properties and are unsafe at 3.0 T. * Pregnant women are not eligible for participating in this study. * Acute claustrophobia
Where this trial is running
New York, New York
- NYU Langone Health — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Eric Sigmund, PhD — NYU Langone Medical Center
- Study coordinator: Nalini Jeet
- Email: Nalini.jeet@nyulangone.org
- Phone: 212-263-0228
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Cancer